--- title: "Cue Biopharma 的股票在一夜之間飆升了超過 65%：是什麼原因導致的？" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/284868524.md" description: "Cue Biopharma Inc. (CUE) 的股價上漲了 67.57%，達到 24.70 美元，此次上漲是由於公司宣佈了一項 3000 萬美元的私人投資、一項二期抗 IgE 抗體的許可，以及任命 Dr. Shao-Lee Lin 為首席執行官。此次 PIPE 融資將支持 Ascendant-221 的開發，這是一種抗 IgE 單克隆抗體，以及公司的整體運營需求。CUE 的市值為 4798 萬美元，過去一年股價下跌了 34.92%，但目前交易價格接近其 52 周高點" datetime: "2026-05-01T05:40:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284868524.md) - [en](https://longbridge.com/en/news/284868524.md) - [zh-HK](https://longbridge.com/zh-HK/news/284868524.md) --- # Cue Biopharma 的股票在一夜之間飆升了超過 65%：是什麼原因導致的？ **Cue Biopharma Inc. ( CUE )** shares surged 67.57% overnight to $24.70 on Thursday after the company simultaneously announced a $30 million private investment in public equity financing, an exclusive Phase 2 anti-IgE antibody license and a CEO appointment. ## $30 Million Raise Funds Pipeline Expansion The PIPE, expected to close around May 4, involves pre-funded warrants for up to 2.72 million shares at an effective price of $11. Net proceeds will be used to support the acquisition and development of **Ascendant-221**, a humanized anti-IgE monoclonal antibody designed to neutralize free IgE and reduce the production of new IgE, targeting major pathways involved in allergic disease. The funds will also be allocated toward general corporate purposes and working capital needs. ## Phase 2 Anti-IgE Asset Separately, CUE licensed Ascendant-221 from the biotechnology company **Ascendant Health Sciences** for a $15 million upfront fee, plus up to $676.5 million in potential development, regulatory and commercial milestone payments. The company also appointed **Shao-Lee Lin**, M.D., Ph.D., as CEO, succeeding interim chief **Lucinda Warren**. Lin previously founded biotechnology company **ACELYRIN** and took it public within three years at a valuation exceeding $2 billion, while contributing to approved medicines including TEPEZZA, SKYRIZI and RINVOQ. ## Trading Metrics, Technical Analysis Cue Biopharma ( CUE ) has a market capitalization of $47.98 million, with a 52-week high of $15.43 and a 52-week low of $0.17. The small-cap stock has declined 34.92% over the past 12 months. Cue Biopharma ( CUE ) is trading at about 95.48% of its 52-week range, indicating it remains closer to the upper end. **Price Action:** CUE closed the regular session up 13.38% at $14.74, according to Benzinga Pro. **Benzinga's Edge Stock Rankings** indicate that CUE is experiencing long-term consolidation along with medium and short-term upward movement.
_Photo courtesy: Shutterstock_ _**Disclaimer:** This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors._ **Read Also: Beyond Meat Stock Is Trending Overnight: Here's What You Should Know** ### 相關股票 - [CUE.US](https://longbridge.com/zh-HK/quote/CUE.US.md) - [SLRN.US](https://longbridge.com/zh-HK/quote/SLRN.US.md) - [BYND.US](https://longbridge.com/zh-HK/quote/BYND.US.md) ## 相關資訊與研究 - [Cue BioPharma 發佈 2026 年第一季度財務業績及近期戰略進展 | CUE 股票新聞](https://longbridge.com/zh-HK/news/286460513.md) - [Cue BioPharma 第一季度淨虧損收窄，研發成本降低](https://longbridge.com/zh-HK/news/286463248.md) - [Cue Biopharma 宣佈進行 3000 萬美元的私募 | CUE 股票新聞](https://longbridge.com/zh-HK/news/284830191.md) - [Cue BioPharma 從 Ascendant 公司獲得抗 IgE 資產的許可；預付款為 1500 萬美元，里程碑付款最高可達 6.765 億美元](https://longbridge.com/zh-HK/news/284906657.md) - [Cue BioPharma 根據納斯達克上市規則 5635(c)(4) 報告了誘導性授予 | CUE 股票新聞](https://longbridge.com/zh-HK/news/285634071.md)